Ozempic (Semaglutide): Mechanisms, Benefits and Risks
- 4 days ago
- 15 min read
In recent years, semaglutide—commercially known as Ozempic, Wegovy, and Rybelsus—has become one of the most discussed medications in modern medicine. Originally developed to treat type 2 diabetes, it has since transformed the fields of obesity treatment, cardiometabolic medicine, and metabolic research.
The reason is simple: semaglutide targets some of the core biological mechanisms behind modern metabolic diseases, rather than only treating their symptoms.
To understand why this drug has become so influential, we first need to understand the diseases it was designed to treat.
The Modern Epidemic of Metabolic Disease
Two closely related conditions—obesity and type 2 diabetes mellitus (T2DM)—have become major global health problems over the past few decades.
In healthy individuals, blood glucose is regulated by hormones produced in the pancreas, particularly within clusters of endocrine cells called islets. These contain two important cell types:
β-cells, which produce insulin, the hormone that allows cells to absorb glucose from the bloodstream
α-cells, which produce glucagon, a hormone that increases blood glucose by stimulating the liver to release stored sugar
Together, these hormones maintain stable blood sugar levels.
In type 2 diabetes, however, the body gradually becomes resistant to insulin—a condition known as insulin resistance. When cells respond poorly to insulin, glucose remains in the bloodstream instead of entering tissues where it can be used for energy. Over time, this leads to chronic hyperglycemia, which can cause complications such as cardiovascular disease, kidney damage, nerve damage, and vision loss.
The scale of the problem is enormous. Today, more than 462 million people worldwide are estimated to live with type 2 diabetes, and the number continues to grow.
Obesity plays a major role in this process. Excess body fat—especially fat stored around internal organs—produces inflammatory signals that worsen insulin resistance and disrupt normal metabolic regulation.
The Evolution of Diabetes Treatment
For many decades, diabetes treatment focused mainly on lowering blood sugar levels. Early therapies included insulin injections and drugs such as metformin, which improve insulin sensitivity.
However, many of these treatments had limitations. Some did not address the underlying metabolic dysfunction, and others even caused weight gain, which can worsen insulin resistance.
A major shift occurred with the discovery of the incretin system, a hormonal signaling pathway that helps regulate glucose after meals. One of the key hormones involved is GLP-1 (glucagon-like peptide-1).
GLP-1 has several important metabolic effects:
stimulates insulin secretion
suppresses glucagon release
slows gastric emptying
reduces appetite and food intake
Because natural GLP-1 is rapidly degraded in the body, researchers developed drugs that mimic its action but remain active for much longer. These drugs are known as GLP-1 receptor agonists. Among them, semaglutide has emerged as one of the most powerful and clinically effective. By influencing appetite, metabolism, and insulin signaling simultaneously, semaglutide represents a major step toward treating the underlying biology of metabolic disease, rather than simply controlling blood sugar levels.
